Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials: Perspective on GLP-1 RA and SGLT-2i therapies

The recent results of Cardiovascular Outcomes Trials (CVOTs) in type 2 diabetes have clearly established the cardiovascular (CV) safety or even the benefit of two therapeutic classes, Glucagon-Like Peptide-1 receptor agonists (GLP-1 RA) and Sodium-Glucose Co-Transporter-2 inhibitors (SGLT-2i). Publi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ludwig, Lisa, Darmon, Patrice, Guerci, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222529/
https://www.ncbi.nlm.nih.gov/pubmed/32404155
http://dx.doi.org/10.1186/s12933-020-01034-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222529/
https://www.ncbi.nlm.nih.gov/pubmed/32404155
http://dx.doi.org/10.1186/s12933-020-01034-3

Ejemplares similares